The Affinity-directed PROtein Missile system is employed and targeted degradation of α-synuclein impedes the pre-formed fibril (PFF)-induced aggregation of α-synuclein in primary neurons derived from rats expressing human α-synuclein.
Abstract
Accumulation of misfolded α-synuclein protein in intracellular inclusion bodies of dopaminergic neurons underlies the pathogenesis of Synucleinopathies, which include Parkinson’s Disease (PD) and Dementia with Lewy Bodies (DLB). Therefore, preventing the accumulation of misfolded α-synuclein in dopaminergic neurons or their clearance could in principle offer intervention strategies against Synucleinopathies, which currently remain untreatable. In this study, we employ the Affinity-directed PROtein Missile (AdPROM) system consisting of the substrate receptor of the CUL2-E3 ligase complex VHL and a nanobody selectively recognising the human α-synuclein protein and demonstrate targeted degradation of endogenous α-synuclein from human cell lines with remarkable selectivity. We further demonstrate that targeted degradation of α-synuclein impedes the pre-formed fibril (PFF)-induced aggregation of α-synuclein in primary neurons derived from rats expressing human α-synuclein. This approach also represents the first demonstration of nanobody-guided proteasomal degradation of some reported clinically relevant α-synuclein variants.
It is proposed that a systems-level approach can be taken where PD is understood as a disease characterized by the imbalance in proteostasis, and potential treatment modalities include small molecules targeting lysosome function, CMA enhancers, gene therapy, and antibodies against extracellular α-synuclein.
Maryam Jabeen, Huma Hameed, Syed Muhammad Ahmad et al.· Neuromolecular medicine· 0 citations
Results indicate α-synuclein clearance and propagation are mediated by glymphatic function and that aquaporin-4 mis-localization observed in the presence of human synucleinopathy may contribute to the development and propagation of Lewy body pathology in conditions such as Lewy body dementia and Parkinson's disease.
Molly Braun, Matthew J. Simon, Jay Jang et al.· Brain Communications· 0 citations
Findings indicate that genotype-specific cellular responses differentially shape the structural properties of released α-syn in a manner that determines amplification responses, enabling inter-group discrimination at the single-molecule level.
Jessica Chedid, Yuan Tang, K. Law et al.· Frontiers in Aging Neuroscie...· 0 citations
This review focuses on translational insights linking α-syn pathology to dysregulated stress-response and protein quality-control pathways, intending to identify potential targets for disease-modifying intervention.
Swaprakash Paul, Abhideep Roy, Pallab Bhattacharya et al.· Current Pharmacology Reports· 0 citations
Based on the structure, a DJ-1-derived peptide (173-180) is designed that significantly inhibited α-synuclein aggregation in TEM and ELISA assays, suggesting its potential as a therapeutic candidate for α-synucleinopathies.
Hyeon Jin Kim, Da Hye Kim, Chang-Woo Han et al.· International Journal of Bio...· 0 citations
Heterotypic interactions with Aβ42 reshape α-syn aggregation pathways and fibril conformations, generating structurally distinct α-syn fibril populations with different neuronal seeding activities, which provide a molecular framework for understanding how cross-talk between amyloidogenic proteins may contribute to stru...
Purnopama Saha, Teshani Liyanaarachchige, Anika Alim et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.